Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian L Dale

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Journal of Medicinal Chemistry|July 11, 2026
TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective AntagonistsMagnus Nilsson, Sara J Bonvini, Emelyne Diers, et al.
Journal of Medicinal Chemistry|September 3, 2025
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human KinomeAvipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Journal of Medicinal Chemistry|July 11, 2026
TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective AntagonistsMagnus Nilsson, Sara J Bonvini, Emelyne Diers, et al.
Journal of Medicinal Chemistry|September 3, 2025
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human KinomeAvipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, et al.
Pageof 2